Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?

Dogansen S. C., Selcukbiricik Ö., Tanrikulu S., Yarman S.

Pituitary, vol.19, no.3, pp.303-10, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 19 Issue: 3
  • Publication Date: 2016
  • Doi Number: 10.1007/s11102-016-0708-3
  • Journal Name: Pituitary
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.303-10
  • Keywords: Prolactinoma, Dopamine agonist withdrawal, Cabergoline, Bromocriptine, Recurrence, LONG-TERM THERAPY, BROMOCRIPTINE TREATMENT, 2ND ATTEMPT, FOLLOW-UP, CABERGOLINE, HYPERPROLACTINEMIA, RECURRENCE, REMISSION, MICROPROLACTINOMAS, MACROPROLACTINOMAS
  • Istanbul University Affiliated: Yes

Abstract

Purpose The aim of the study was to assess the effect of dopamine agonist (DA) withdrawal, the current recurrence rate of hyperprolactinemia, and possible factors that predict recurrence in patients with prolactinoma.